Event-free survival at 12 months is a strong surrogate endpoint for stage 1 diffuse large B cell lymphoma: a report from Nation Wide Registry Thai Lymphoma Study Group

• Main Authors: Kitsada Wudhikarn, Udomsak Bunworasate, Jakrawadee Julamanee, Arnuparp Lekhakula, Supachai Ekwattanakit, Archrob Khuhapinant, Pimjai Niparuck, Suporn Chuncharunee, Tontanai Numbenjapon, Kannadit Prayongratana, Nonglak Kanitsap, Somchai Wongkhantee, Nisa Makruasi, Peerapon Wong, Lalita Norasetthada, Weerasak Nawarawong, Chittima Sirijerachai, Kanchana Chansung, Tawatchai Suwanban, Pannee Praditsuktavorn, Tanin Intragumtornchai
• Format: Journal
• Published: 2020
• Subjects: Biochemistry, Genetics and Molecular Biology; Medicine
• Online Access: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85087357897&origin=inward; http://cmuir.cmu.ac.th/jspui/handle/6653943832/70283
• Institution: Chiang Mai University

© 2020, © 2020 Informa UK Limited, trading as Taylor & Francis Group. Event-free survival at 12 months (EFS12) is a surrogate endpoint for long-term outcomes in many histologic lymphoma subtypes. However, most reports have primarily investigated the implication of EFS12 in advanced-stage non-H...